Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
olaparib + cetuximab + radiation therapy
- Development stage
- Unknown
- Lead developer
- University of Colorado Denver
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This therapeutic regimen is a combination of the PARP inhibitor olaparib, the anti-EGFR monoclonal antibody cetuximab, and radiation therapy, specifically evaluated for the treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC) in patients with heavy smoking histories. Olaparib acts as a radiosensitizer by inhibiting PARP-1 and PARP-2 enzymes, which are critical for repairing single-strand DNA breaks, thereby enhancing the lethal effects of radiation-induced DNA damage. Cetuximab targets the epidermal growth factor receptor (EGFR), which is frequently overexpressed in HNSCC and associated with resistance to radiation. The combination aims to overcome treatment resistance and improve survival outcomes in a high-risk patient population where standard chemoradiation may be less effective.
- Brand names
- LynparzaErbitux
- Other names
- olaparibcetuximabintensity-modulated radiation therapyIMRT
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)PARP2 (Poly (adp-ribose) polymerase 2)DNA
Beyond the preview
Go deeper on olaparib + cetuximab + radiation therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on olaparib + cetuximab + radiation therapy.